SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Elmer who wrote (6745)7/17/2002 12:48:54 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
David,

Insiders are probably as shell-shocked as the rest of us. The last few days certainly have been an improvement, though.

Note that the relative valuation of the BTK index compared with the DRG index has actually been pretty flat the last few years - the ratio is currently around 1.25, which is about where it was in April 2000 in the aftermath of the biotech bubble as well as in Jan 2001. (But note part of this is because of the recent collapse of the DRG index and note also that the BTK understates the carnage in the average small biotech). Meanwhile, the NASDAQ has continued to deteriorate relative to the Dow, which in the past would mean the BTK would decline relative to the DRG index.

Peter



To: Elmer who wrote (6745)7/18/2002 1:16:38 PM
From: Zirdu  Respond to of 52153
 
There is insider buying in GNVC. Probably not on your list as it is a very small cap. (64 million market cap.)



To: Elmer who wrote (6745)7/18/2002 1:26:37 PM
From: Tomato  Read Replies (2) | Respond to of 52153
 
I don't have it in front of me, but I'm pretty sure that the insider chart in the latest Barron's showed a couple of nice sized buys from LEXG insiders.